PROTACs (Proteolysis Targeting Chimeras) are small molecules that direct the cell's natural protein destruction machinery to degrade specific disease-causing proteins. They work by linking a target protein to an E3 ubiquitin ligase, marking the protein for degradation.
PROTACs function through a three-step process:
The PROTAC itself is recycled and can repeat the process, making it highly efficient.
PROTACs can be categorized based on their structure and the E3 ligases they recruit:
| Type | E3 Ligase Recruited | Example Target Protein |
|---|---|---|
| Peptide-based PROTACs | VHL (von Hippel-Lindau) | Estrogen receptor |
| Small-molecule PROTACs | CRBN (Cereblon) | BRD4 (a protein involved in cancer) |
| Clipping PROTACs | Multiple E3 ligases | Kinases and other enzymes |
Each type has advantages depending on the target protein and the desired therapeutic effect.
PROTACs are primarily used in drug discovery to target proteins that are difficult to inhibit with traditional small-molecule drugs. For example, ARV-471, a PROTAC developed by Arvinas, targets the estrogen receptor for the treatment of breast cancer.
Researchers are also exploring PROTACs for neurodegenerative diseases, such as Alzheimer's, by targeting toxic proteins like tau or amyloid-beta.
One common misconception is that PROTACs permanently disable proteins. In reality, they temporarily reduce protein levels, allowing the cell to regulate protein abundance dynamically.
Another myth is that PROTACs are only useful for cancer therapy. While they are widely studied for oncology, their applications extend to inflammatory diseases, infections, and genetic disorders.
In 2020, the first PROTAC-based drug, ARV-471, entered clinical trials for breast cancer. This drug specifically targets the estrogen receptor, reducing its levels in cancer cells and slowing tumor growth. The success of ARV-471 has paved the way for further research into PROTACs for other diseases.
PROTACs represent a new approach in drug discovery, offering a precise and efficient way to target and degrade disease-causing proteins. Their versatility and potential applications make them a promising tool in modern medicine.